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Health-related quality of life (HRQoL) is severely impaired in persons receiving dialysis. 20 
Malnutrition has been associated with some measures of poor HRQoL in cross-sectional 21 
analyses in dialysis populations, but no studies have assessed the impact of malnutrition and 22 
dietary intake on change in multiple measures of HRQoL over time. We investigated the 23 
most important determinants of poor HRQoL and the predictors of change in HRQoL over 24 
time using several measures of HRQoL. We enrolled 119 haemodialysis and 31 peritoneal 25 
dialysis patients in this prospective study. Nutritional assessments (Subjective Global 26 
Assessment [SGA], anthropometry and 24-hour dietary recalls) and HRQoL questionnaires 27 
(Short Form-36 [SF-36] mental [MCS] and physical component scores [PCS] and European 28 
QoL-5 Dimensions [EQ5D] health state [HSS] and visual analogue scores [VAS]) were 29 
performed at baseline, 6 and 12 months. Mean age was 64(14) years. Malnutrition was 30 
present in 37% of the population. At baseline, malnutrition assessed by SGA was the only 31 
factor independently (and negatively) associated with all four measures of HRQoL. No single 32 
factor was independently associated with decrease in all measures of HRQoL over 1 year. 33 
However, prevalence/development of malnutrition over one year was an independent 34 
predictor of 1-year decrease in EQ5D HSS and 1-year decrease in fat intake independently 35 
predicted the 1-year decline in SF-36 MCS and PCS, and EQ5D VAS. These findings 36 
strengthen the importance of monitoring for malnutrition and providing nutritional advice to 37 
all persons on dialysis. Future studies are needed to evaluate the impact of nutritional 38 
interventions on HRQoL and other long-term outcomes. 39 





Health-related quality of life (HRQoL) is one of the most important and widely used patient-42 
centred outcome measures in renal research and clinical settings that provides information 43 
about an individual’s well-being with respect to physical, mental, social and somatic domains 44 
of health1. HRQoL is severely impaired in persons receiving dialysis compared to the general 45 
population2 and decreased HRQoL has been associated with increased number of 46 
hospitalizations and poor survival in persons receiving haemodialysis (HD) and performing 47 
peritoneal dialysis (PD)3, 4. Several factors have been identified as important determinants of 48 
poor HRQoL in persons on dialysis, including older age, female sex, unemployment, lack of 49 
educational qualifications, anaemia, presence of diabetes and other comorbidities, lack of 50 
sleep, depression and poor nutritional status2, 5-7. 51 
 52 
Malnutrition is a common and major complication, as well as an independent risk factor for 53 
increased mortality in the dialysis population8. Several terms for referring to malnutrition 54 
have been used in both the renal dietetic practice and research. However, in 2008 the 55 
International Society of Renal Nutrition and Metabolism suggested a single term, “Protein-56 
energy wasting (PEW)”9, which has improved communication and clarified thinking across 57 
renal multidisciplinary care teams. For the purpose of this study, the term “malnutrition” will 58 
be used as a synonymous with “PEW”. The pathogenesis of malnutrition is complex and 59 
results from the interaction of several factors such as loss of appetite causing poor nutritional 60 
intake, loss of protein and micronutrients during dialysis, increased inflammation and 61 
oxidative stress, presence of comorbidities and decreased physical activity10. Previous cross-62 
sectional analyses have reported that HRQoL, as assessed by the 36-Item Short Form Health 63 
Survey (SF-36), Kidney Disease Quality of Life Short Form or the European Quality of Life 64 




dialysis compared to those who were well-nourished5, 6, 11-15. However, none of these studies 66 
included a comprehensive assessment of dietary intake and all used a single instrument to 67 
assess HRQoL. Hence, further evidence is needed regarding the impact of malnutrition and 68 
dietary intake on HRQoL. 69 
 70 
It has been previously reported that HRQoL declines over time in persons receiving 71 
dialysis16, 17, but factors that contribute to changes in HRQoL over time, in particular 72 
measures of nutritional status, have not been adequately investigated. We therefore sought to 73 
determine the most important determinants of poor HRQoL, as well as the predictors of 74 
change in HRQoL over time in persons receiving dialysis in a prospective study, with a 75 
particular focus on dietary intake and malnutrition. 76 
 77 
MATERIALS AND METHODS 78 
Patient population 79 
One hundred nineteen HD and 31 PD patients who were ≥18 years of age, had a dialysis 80 
vintage greater than 3 months or were starting either HD or PD treatment, and were able to 81 
give written informed consent were enrolled in this one-year single-centre prospective 82 
observational study conducted in the Department of Renal Medicine, Royal Derby Hospital. 83 
Recruitment was from September 2016 to August 2017. Persons receiving HD used high-flux 84 
polysulphone, polyarylethersulfone or polyvinylpyrrolidone dialyzers and were dialyzed at 85 
least three times per week for 3-4 hours. Persons performing PD used lactate/bicarbonate-86 
buffered 1.36% and 3.86% glucose (Physioneal; Baxter®), 7.5% icodextrin (Extraneal; 87 
Baxter®) and/or 1.1% aminoacid-containing solutions (Nutrineal; Baxter®). The exclusion 88 
criteria were pregnancy or intending pregnancy, breastfeeding and hospitalisation at the time 89 




Declaration of Helsinki and all procedures involving patients were approved by the local 91 
Research Ethics Committee (East Midlands – Nottingham 1. REC reference: 16/EM/0243). 92 
Written informed consent was obtained from all patients. 93 
 94 
Sociodemographic and medical characteristics 95 
Baseline sociodemographic characteristics including chronological age, sex, ethnicity, 96 
educational level and employment status, as well as present co-morbidities, history of 97 
cardiovascular disease, blood results and time since first dialysis treatment (i.e., dialysis 98 
vintage) were collected from direct interview and/or electronic medical records. 99 
 100 
Nutritional assessments 101 
At baseline, 6 and 12 months, we conducted the following detailed nutritional assessments: 102 
 103 
- Dietary intake: Twenty four-hour dietary recalls were used for dietary intake 104 
assessment. From each participant, an experienced dietitian collected precise and 105 
comprehensive information regarding food and drink intake during a 24-hour period. 106 
In persons receiving HD, 24-hour dietary recalls included information from a dialysis 107 
day, a non-dialysis day and a weekend day, while in persons performing PD, dietary 108 
recalls obtained information from two weekdays and one weekend day. We used the 109 
software Dietplan 7 (Forestfield Software Limited, West Sussex, United Kingdom) to 110 
calculate the average intake of calories, protein and fat. Average energy and protein 111 
intake was then expressed in daily kilocalories and grams, respectively, per kilogram 112 





- Anthropometry: International standards for anthropometric assessment18 were 115 
followed to measure post-dialysis weight, height, mid-arm circumference (MAC) and 116 
triceps skinfold thickness (TSF). Weight and height were used to calculate body mass 117 
index (BMI; reported in kg/m2). Mid-arm muscle circumference (MAMC) was 118 
calculated using the following equation: MAMC (cm2) = MAC – (3.14 * TSF), where 119 
MAC and TSF were measured in cm. 120 
 121 
- Handgrip strength (HGS): We used the Takei 5401 handgrip digital dynamometer 122 
(Takei Scientific Instruments Co., Ltd., Tokyo, Japan) to measure HGS within the 123 
first hour of HD treatment or during PD clinic visits. HGS measurement was 124 
conducted in the non-fistula arm or the dominant arm if this did not have a fistula as 125 
previously described19. 126 
 127 
- Subjective Global Assessment (SGA): An experienced dietitian conducted the 128 
validated 7-point scale SGA20, 21 for the assessment of nutritional status. The 7-point 129 
scale SGA is comprised of six elements (weight change, dietary intake, 130 
gastrointestinal symptoms, functional capacity, comorbidities, and physical 131 
examination), which are scored between 1 and 7 in order to determine the overall 132 
SGA score. The lower the overall SGA score, the more severe the degree of 133 
malnutrition. For baseline analysis, participants were classified as being well-134 
nourished (SGA scores 6-7) or malnourished (SGA score <5). For further analysis, 135 
participants who completed 12 months of follow-up were classified according to their 136 
nutritional status over 1 year into two groups: a) “stayed or became well-nourished” - 137 
participants who were well-nourished throughout the one year or became well-138 




at 6 or 12 months); b) “stayed or became malnourished” – participants who were 140 
malnourished throughout the one year or who became malnourished at either 6 or 12 141 
months (i.e., well-nourished at baseline but malnourished at 6 or 12 months). As part 142 
of their routine clinical care, all malnourished patients received dietetic advice by 143 
their usual renal dietitian, which may have included the use of nutritional 144 
supplements; however, we did not assess the impact of specific nutritional 145 
supplements in our analyses. 146 
 147 
Quality of life assessments 148 
HRQoL was assessed at baseline, 6 and 12 months using the SF-36 survey and the EQ5D 149 
questionnaire, which are validated and standardized instruments that have been widely used 150 
to assess HRQoL in the general and dialysis populations11, 22-24.  151 
 152 
The SF-36 survey comprises 36 questions that assess eight health state domains: physical 153 
functioning, role physical, bodily pain, general health, vitality, social functioning, role 154 
emotional, and mental health. These eight domains are then summarized into two scores: the 155 
physical component score (PCS) and the mental component score (MCS)22. Both the PCS 156 
and MCS were calculated according to well-defined guidelines25-27. In brief, 10 questions of 157 
the SF-36 survey were first recoded so that a higher score represented a better health state 158 
(e.g. question #7 regarding bodily pain was recoded so that a high score indicated no pain at 159 
all). Next, raw scores for each health state domain were calculated by summing across items 160 
in the same health state domain (e.g. role physical = scores from questions 4a+4b+4c+4d), 161 
and then raw scores were transformed to a 0-100 scale25. Each of the eight SF-36 transformed 162 
scales were then standardized using a z-score transformation and the means and standard 163 




were calculated by multiplying each scale z-score by their respective physical and mental 165 
factor score coefficients and summing the eight products. Finally, both the PCS and MCS 166 
were standardized to a T-score by multiplying by 10 and adding the resultant product to 5027. 167 
A PCS or MCS score above or below 50 is therefore above or below the average for the 168 
general population. 169 
 170 
The EQ5D questionnaire consists of a health state score (HSS) and a visual analogue score 171 
(VAS). The HSS comprises five dimensions (i.e. mobility, self-care, usual activities, 172 
pain/discomfort, and anxiety/depression) with five available response levels (i.e. no, slight, 173 
moderate, severe, and extreme problems/unable to). The HSS is calculated using specific 174 
coefficients for the five dimensions and response levels as described elsewhere23, and it 175 
ranges from -0.285 (for the worst health state) to 1 (for the best health state). The VAS uses a 176 
thermometer-like scale numbered from 0 to 100 to grade the current health status of 177 
individuals; the higher the VAS the better the health state. 178 
 179 
Statistical analyses 180 
All statistical analyses were conducted using the statistical software SPSS version 25.0 (IBM 181 
Corporation, Chicago, IL). Continuous variables are presented as mean (standard deviation) 182 
or median (interquartile range [IQR]), while categorical variables are presented as 183 
percentages. Missing data were omitted (C reactive protein [CRP], n=7 and HGS, n=6). 184 
Paired t-test and Wilcoxon test were used for intragroup comparisons in the case of 185 
continuous variables. Student t-test and Mann-Whitney U test were used for intergroup 186 
comparisons for continuous variables and Chi-squared test or Fisher’s exact test for 187 
categorical variables. To determine the significance and strength of associations between 188 




Multivariable linear regression analyses were performed to identify the independent 190 
determinants associated with HRQoL at baseline. Adjusted R2, unstandardized (B) and 191 
standardized (Beta) coefficients were reported. 192 
 193 
Change in HRQoL over one year was defined as a 5-point change (increase or decrease) in 194 
the SF-36 MCS, SF-36 PCS and EQ5D VAS, and a 0.037 change (improvement or 195 
deterioration) in the EQ5D HSS. These thresholds represent the Minimally Important 196 
Difference (MID) defined as the smallest change in the HRQoL score of interest which a 197 
patient perceives as meaningful or beneficial28. In terms of supporting the interpretability of 198 
the change in HRQoL, it has been suggested that using the MID is better than using the 199 
clinically important difference (i.e. change or difference associated with outcomes), though 200 
these are in fact similar28-31. For statistical analysis, participants were grouped into those with 201 
an increase in or stable HRQoL scores over time versus a decrease in HRQoL scores. 202 
Multivariable logistic regression analyses were conducted to identify the independent 203 
predictors of increased/stable HRQoL versus decreased HRQoL over one year. Nagelkerke 204 
R2 for the models and Hosmer and Lemeshow test p-value were reported. 205 
 206 
Independent variables included in the multivariable linear and logistic regression analyses 207 
were selected on the basis of significant associations in univariable analyses or biological 208 
plausibility (i.e., chronological age, sex and employment status). For all statistical analyses, a 209 
p-value <0.05 was considered to have statistical significance.  210 
 211 
Our original sample size determination was performed for an observational study with 212 
mortality as the primary outcome32. However, for the purpose of this analysis, we conducted 213 




primary outcomes. With a sample size of 117 participants split in two groups (Group 1: 215 
stayed well-nourished + became well-nourished over 1 year, n=90; Group 2: stayed 216 
malnourished + became malnourished over 1 year, n=27), the analysis would hypothetically 217 
have had 80% power to detect odds ratios of 3.45, 3.47, 3.57 and 3.51 for the decrease in 218 
MCS, PCS, HSS and VAS, respectively (STATA, version 16.1; StataCorp LLC, Houston, 219 
TX, USA). 220 
 221 
RESULTS 222 
Baseline participant characteristics 223 
Baseline characteristics of 119 HD and 31 PD participants are summarized in Table 1. Mean 224 
age of the whole study population was 64 (14) years. Thirty-six percent of the participants 225 
were female and 41% had been diagnosed with diabetes. The majority of the participants 226 
were White British (88%), unemployed or retired (75%) and had some level of education 227 
(57%). Malnutrition (as determined by 7-point SGA) was present in 37% of the population. 228 
Mean PCS and MCS were 25.4 (13.1) and 47.4 (12.1), respectively, which were lower than 229 
values for healthy UK volunteers aged 18-64 years (i.e. 50 [10] for both scores)27. EQ5D 230 
HSS (0.742, IQR 0.494 to 0.873) and VAS (60, IQR 49.8 to 80) were also lower than 231 
reported for the general UK population (n=3381; HSS 0.86 [0.23], VAS 82.5 [16.9])33, 34. 232 
 233 
Determinants of health-related quality of life 234 
Table 2 shows associations with HRQoL at baseline in univariable analysis. Only 235 
malnutrition assessed by SGA was strongly associated with worse scores in all HRQoL 236 
measures in comparison with those participants who were well-nourished. Additionally, SGA 237 
score showed strong positive correlations with all HRQoL scores. Unemployed/retired 238 




employed participants and those without diabetes, respectively. Coronary heart disease 240 
(CHD), longer dialysis vintage and being on HD were associated with lower PCS and EQ5D 241 
HSS. Age was positively associated with MCS and EQ5D HSS. Males showed higher PCS in 242 
comparison with females. Lower CRP and higher serum albumin and serum creatinine were 243 
associated with higher PCS. Other markers of nutritional status including protein intake and 244 
HGS associated with two of the four HRQoL measures. 245 
 246 
In multivariable linear regression analyses (Table 3), nutritional status was the only 247 
determinant independently associated with all four HRQoL measures at baseline, such that 248 
malnutrition was associated with lower scores. Diabetes was an independent determinant of 249 
decreased PCS and both EQ5D scores, whereas being unemployed or retired was 250 
independently associated with lower PCS and EQ5D VAS. Older age was found to be an 251 
independent determinant of better MCS and EQ5D HSS, while being on HD showed an 252 
independent association with worse PCS and EQ5D HSS. In another multivariable model that 253 
included SGA as a continuous variable, a low SGA score was independently associated with 254 
worse HRQoL in all four measures (Supplementary Table 1).  255 
  256 
Predictors of change in health-related quality of life 257 
During follow-up, 18 participants died, 12 received a kidney transplant, 2 withdrew their 258 
consent and 1 recovered kidney function sufficiently to discontinue dialysis. Thus, 117 259 
participants completed one year of follow-up (Figure 1). There were no significant changes in 260 
mean MCS and PCS or median EQ5D VAS, at 12 months compared to baseline (47.6 [12.1] 261 
vs. 46.5 [12.9], 25.7 [12.5] vs. 24.1 [13.5], 60 [50 to 77.5] vs. 55 [40 to 75]; p>0.05 for all 262 
comparisons); however, median EQ5D HSS decreased significantly at one year in 263 





Univariable analysis showed that participants who stayed or became malnourished during one 266 
year (n=27) were more likely to evidence a decrease in EQ5D HSS (70% vs. 43%; p=0.01) at 267 
12 months compared to those who stayed or became well-nourished during one year (n=90). 268 
Univariable analysis also showed that those participants who had a decrease in energy and fat 269 
intake over one year had a decrease in three of the four HRQoL measures at 12 months 270 
compared to those who had an increase in calorie and fat intake over one year. Additionally, 271 
1-year decrease in serum total protein and haemoglobin were associated with the 1-year 272 
decline in PCS. Furthermore, participants with CHD evidenced a greater proportion with the 273 
1-year decrease in MCS and EQ5D VAS, while lack of educational qualifications was 274 
associated with the 1-year decline in EQ5D VAS. No associations were observed with other 275 
potential risk factors, including chronological age, sex, employment status, presence of 276 
diabetes and dialysis modality (Supplementary Table 2).  277 
 278 
Table 4 summarizes the multivariable logistic regression analyses to identify independent 279 
predictors of decrease in HRQoL over one year. No single factor was independently 280 
associated with decrease in all measures of HRQoL. However, prevalence or development of 281 
malnutrition over one year was an independent predictor of the 1-year decrease in EQ5D HSS 282 
and a decrease in fat intake over one year independently predicted the 1-year decline in MCS, 283 
PCS and EQ5D VAS. Lack of educational qualifications and presence of CHD each 284 
independently predicted a decrease in EQ5D VAS. 285 
 286 
DISCUSSION 287 
In this prospective study, we observed that the presence of malnutrition was the most 288 




EQ5D in persons on dialysis at baseline. Additionally, prevalence/development of 290 
malnutrition over one year was an independent predictor of  the 1-year decrease in EQ5D 291 
HSS and a decrease in fat intake (a marker of deteriorating nutritional intake) independently 292 
predicted decreases in MCS, PCS and EQ5D VAS. 293 
 294 
Malnutrition is one of the major and most frequent complications observed in persons 295 
receiving dialysis that is also often underrecognized and neglected. It is clinically important 296 
because it is associated with poor survival and decreased HRQoL8. The relationship between 297 
malnutrition and decreased HRQoL in the dialysis population has been previously 298 
investigated only in cross-sectional analyses. Gunalay et al.11 observed that malnourished 299 
persons on HD and performing PD had significantly lower EQ5D scores (both HSS and 300 
VAS) compared to those who were well-nourished. A cross-sectional analysis of the 301 
Convective Transport Study reported that a higher SGA score was independently associated 302 
with higher SF-36 PCS and MCS, after adjusting for covariates13. Several other studies have 303 
also reported that a low SGA score and/or a high Malnutrition Inflammation Score (a 304 
modified version of the SGA) correlates with lower SF-36 PCS and MCS5, 6, 12, 14. Our study 305 
adds to published data by showing that malnutrition at baseline was an independent 306 
determinant of decreased HRQoL across all domains and using two different measures (SF-307 
36 and EQ5D) whereas previous studies have used only one measure or have reported 308 
associations with some but not all measures15. Moreover, our analysis was adjusted for other 309 
important determinants of HRQoL including chronological age, sex, presence of diabetes, 310 
employment status, dialysis modality, dialysis vintage and HGS. Additionally, we have 311 
confirmed an association between the severity of malnutrition and HRQoL as shown by the 312 





We observed that EQ5D HSS (which includes physical and psychosocial variables) decreased 315 
over one year in the whole cohort, though no change in mean MCS and PCS or median 316 
EQ5D VAS was observed. This may be in part because participants with decreasing HRQoL 317 
may have been more likely to die during the observation period. Previous prospective studies 318 
have reported that persons on dialysis experience a decline in the physical and mental 319 
components of HRQoL over time16, 17; however, they did not explore the factors associated 320 
with this decrease, particularly those related to dietary intake and malnutrition. Additionally, 321 
previous prospective studies have observed an independent association between malnutrition 322 
and decreased PCS and MCS only at baseline12, 14, but did not assess the impact of 323 
malnutrition on change in HRQoL over time. We have now helped to fill this knowledge gap 324 
by showing that prevalence/development of malnutrition over one year was an independent 325 
predictor of the 1-year decrease in EQ5D HSS, and the 1-year decrease in fat intake (a 326 
measure of nutritional intake that contributes significantly to calorie intake) was 327 
independently associated with the 1-year decline of MCS, PCS and EQ5D VAS. Inadequate 328 
dietary intake is an important marker of malnutrition and is associated with poor outcomes8. 329 
We observed that energy and protein intake were low at baseline compared to the 330 
recommended intake for persons receiving dialysis35. Lower protein intake correlated with 331 
lower PCS and EQ5D HSS at baseline and a decrease in energy intake over 1 year also 332 
correlated with the 1-year decrease in MCS and both EQ5D scores in univariable analyses but 333 
change in energy and protein intake did not enter the final multivariable models. These 334 
observations reinforce the need to conduct comprehensive nutritional screening and 335 
monitoring to identify those persons on dialysis at nutritional risk or already malnourished, 336 
and then implement appropriate nutritional interventions to prevent malnutrition or improve 337 
nutritional status. This approach would be expected to improve HRQoL and clinical 338 





Similar to other studies conducted in dialysis populations2, 16, 24, 36, 37, we observed that 341 
diabetes, being on HD and unemployment status were independently associated with lower 342 
HRQoL scores at baseline. Also as reported in previous studies38, 39, older age was an 343 
independent determinant of better MCS, PCS and EQ5D HSS. One possible explanation may 344 
be that older people are more accepting of the limitations caused by illness and have lower 345 
expectations of HRQoL, but this requires further investigation. Similar to our findings, 346 
previous studies have confirmed that low educational level and presence of cardiovascular 347 
disease are independently associated with lower HRQoL scores40, 41. 348 
 349 
Several limitations need to be considered when interpreting our results. Owing to the 350 
observational nature of this study, we cannot infer a causal relationship between malnutrition 351 
and HRQoL. Prospective clinical trials will be needed to investigate this further. The 352 
relatively small sample size prevented us from including more potential determinants of 353 
HRQoL in multivariable analyses. This may in part account for the relatively low adjusted R2 354 
values in the multivariable analyses, suggesting the presence of residual confounding, and 355 
may have also resulted in a failure to detect associations between some variables and 356 
decrease in HRQoL scores. As this was a single centre study, our results cannot necessarily 357 
be extrapolated to other dialysis populations. Thus, larger multicentre studies are needed to 358 
confirm these findings. We did not use the Kidney Disease Quality of Life (KDQOL) survey 359 
and therefore could not assess the impact of malnutrition on the kidney-specific QoL 360 
domains. However, the SF-36 questionnaire, which is included in the KDQOL survey as a 361 
generic chronic disease core component, is a widely used HRQoL instrument that has been 362 
validated in multicultural environments with large general population samples, as well as in 363 




statistical analyses and thus the borderline “significant” associations that we observed could 365 
be due to chance. We have not adjusted p-values (e.g. Bonferroni correction)42-45 but have 366 
interpreted our results with caution in the light of multiple testing.  367 
 368 
In conclusion, these findings strengthen the importance of undertaking nutritional screening 369 
and monitoring in all persons on dialysis to identify malnutrition, and providing specialised, 370 
individualised nutritional advice in order to prevent malnutrition and/or improve nutritional 371 
status. Further prospective clinical trials with larger sample sizes and longer follow-up are 372 
needed to evaluate the impact of dietetic interventions on HRQoL and other clinical 373 
outcomes. 374 
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Table 1. Baseline participant characteristics including demographics, clinical, biochemical, 503 
nutritional and health-related quality of life scores. 504 
 505 
Variable n=150 
Age (years) 64 (14) 
Female [n (%)] 54 (36) 
White British [n (%)] 132 (88) 
Educational qualifications [n (%)] 85 (57) 
Unemployed/retired [n (%)] 113 (75) 
Diabetes [n (%)] 61 (41) 
Coronary heart disease [n (%)] 60 (40) 
Malnutrition [n (%)] 55 (37) 
Dialysis vintage (months) 29 (IQR 10 to 68) 
Haemoglobin (g/L) 117 (13) 
Serum albumin (g/L) 31.6 (4.5) 
C reactive protein (mg/L) 8 (4 to 17) 
Total cholesterol (mmol/L) 4.1 (1.2) 
Serum creatinine (µmol/L) 647 (214) 
Serum phosphate (mmol/L) 1.56 (0.51) 
Serum potassium (mmol/L) 4.6 (0.7) 
Energy intake (kcal/kg/day) 21.0 (7.6) 
Protein intake (g/kg/day) 0.88 (0.29) 
Fat intake (g/day) 58.1 (29.8) 
Post-dialysis weight (kg) 79.4 (20.8) 
Body mass index (kg/m2) 27.7 (6.3) 
Handgrip strength (kg) 23.1 (11.5) 
Mid-arm muscle circumference (cm2) 25.6 (3.8) 
Triceps skinfold thickness (mm) 17.2 (7.2)  
SF-36 Mental component score 47.4 (12.1) 
SF-36 Physical component score 25.4 (13.1) 
EQ5D Health state score 0.742 (0.494 to 0.873) 
EQ5D Visual analogue score 60 (49.8 to 80) 
Data are expressed as mean (standard deviation), median (interquartile range) or percentages, as appropriate. 506 







Table 2. Determinants of health-related quality of life in univariable analysis at baseline in persons receiving dialysis. 511 
 512 
Factor 
Dialysis patients (n=150) 
Mental component score Physical component score EQ5D Health state score EQ5D visual analogue score 













0.697 (0.419 to 0.816) 
0.781 (0.590 to 0.879) 
0.07 
 
60 (50 to 75) 
62.5 (45 to 80) 
0.7 












0.524 (0.305 to 0.727) 
0.816 (0.662 to 0.892) 
<0.0001 
 
50 (30 to 60) 














0.650 (0.352 to 0.795) 
0.801 (0.644 to 0.879) 
<0.0001 
 
50 (32.5 to 75) 
65 (50 to 80) 
0.04 












0.700 (0.390 to 0.808) 




60 (41.3 to 75) 














0.704 (0.454 to 0.861) 




60 (45 to 75) 














0.777 (0.520 to 0.872) 
0.727 (0.475 to 874) 
0.7 
 
65 (50 to 80) 
















0.801 (0.687 to 0.907) 




80 (50 to 85) 
60 (45 to 75) 
 
0.004 
 Pearson’s r p Value Pearson’s r p Value Spearman's Rho p Value Spearman's Rho p Value 
Age (years) 0.371 <0.0001 0.058 0.5 0.214 0.009 0.146 0.08 
SGA score 0.332 <0.0001 0.473 <0.0001 0.484 <0.0001 0.392 <0.0001 
Dialysis vintage (months) 0.056 0.5 -0.183 0.03 -0.165 0.04 0.050 0.5 
C reactive protein (mg/L) 0.094 0.3 -0.187 0.03 -0.137 0.1 -0.102 0.2 
Haemoglobin (g/L) 0.040 0.6 0.122 0.1 0.069 0.4 0.081 0.3 
Serum creatinine (µmol/L) -0.075 0.4 0.193 0.02 0.114 0.2 0.141 0.09 
Serum albumin (g/L) 0.091 0.3 0.171 0.04 0.142 0.08 0.128 0.1 
Total cholesterol (mmol/L) -0.110 0.2 0.060 0.5 0.105 0.2 0.098 0.2 
Energy intake (kcal/day) 0.085 0.3 0.115 0.2 0.162 0.05 0.084 0.3 
Protein intake (g/day) 0.102 0.2 0.167 0.04 0.175 0.03 0.117 0.2 
Fat intake (g/day) 0.042 0.6 0.045 0.6 0.071 0.4 -0.014 0.9 
Body mass index (kg/m2) 0.029 0.7 -0.002 1.0 -0.007 0.9 -0.009 0.9 
Handgrip strength (kg) -0.014 0.9 0.361 <0.0001 0.279 <0.0001 0.107 0.2 
MAMC (cm2) -0.013 0.9 0.051 0.5 0.002 1.0 0.033 0.7 










Mental component score Physical component score EQ5D Health state score EQ5D Visual analogue score 
B Beta p Value B Beta p Value B Beta p Value B Beta p Value 
Age (years) 0.334 0.373 <0.0001 0.092 0.094 0.2 0.005 0.259 0.002 0.230 0.138 0.1 
Sex (Female vs. Male) -0.626 -0.025 0.8 -0.633 -0.023 0.8 -0.075 -0.126 0.2 -5.026 -0.106 0.3 
Unemployed/retired (Yes vs. No) -2.278 -0.082 0.3 -4.603 -0.153 0.04 -0.051 -0.079 0.3 -9.314 -0.181 0.03 
Dialysis modality (HD vs. PD) -0.624 -0.021 0.8 -4.937 -0.154 0.03 -0.117 -0.171 0.02 -6.113 -0.112 0.2 
Nutritional status (Malnourished vs. 
Well-nourished) 
-7.984 -0.316 <0.0001 -10.68 -0.389 <0.0001 -0.225 -0.384 <0.0001 -19.32 -0.410 <0.0001 
Diabetes (Yes vs. No) -1.202 -0.049 0.5 -6.166 -0.231 0.002 -0.151 -0.264 <0.0001 -9.047 -0.198 0.01 
Dialysis vintage (months) 0.013 0.070 0.4 -0.017 -0.086 0.2 0.000 -0.064 0.4 0.019 0.055 0.5 
Handgrip strength (kg) -0.009 -0.009 0.9 0.173 0.150 0.1 0.005 0.184 0.06 -0.093 -0.047 0.7 
Adjusted R2 0.212 0.341 0.352 0.223 
 518 
Results presented as unstandardized (B) and standardized (Beta) coefficients.  519 
Abbreviations: EQ5D, European Quality of Life 5-Dimensions; HD, haemodialysis; PD, peritoneal dialysis. 520 





Table 4. Multivariable logistic regression analyses showing independent predictors of decrease in health-related quality of life scores over one 523 




Decrease in MCS Decrease in PCS Decrease in EQ5D HSS Decrease in EQ5D VAS 
OR 95% CI p Value OR 95% CI p Value OR 95% CI p Value OR 95% CI p Value 
Sex (Female vs. Male) 1.45 0.61 – 3.48 0.4 0.82 0.36 – 1.87 0.6 1.47 0.65 – 3.34 0.4 1.06 0.46 – 2.45 0.9 
Educational qualifications (No vs. Yes) 0.81 0.35 – 1.86 0.6 1.11 0.49 – 2.48 0.8 1.87 0.85 – 4.14 0.1 2.40 1.06 – 5.41 0.04 
Coronary heart disease (Yes vs. No) 2.16 0.94 – 4.97 0.07 0.98 0.43 – 2.25 1.0 1.59 0.70 – 3.58 0.3 2.37 1.03 – 5.47 0.04 
Nutritional status over 1 year (Stayed or became 
malnourished vs. stayed or became well-nourished) 
1.87 0.73 – 4.81 0.2 0.84 0.32 – 2.16 0.7 3.04 1.16 – 7.98 0.02 1.99 0.76 – 5.20 0.2 
1-year decrease serum total protein (Yes vs. No) 1.98 0.88 – 4.46 0.1 2.16 0.98 – 4.79 0.06 1.27 0.58 – 2.75 0.6 0.84 0.37 – 1.89 0.7 
1-year decrease in fat intake (Yes vs. No) 2.72 1.20 – 6.18 0.02 2.29 1.03 – 5.08 0.04 1.81 0.82 – 3.98 0.1 2.77 1.23 – 6.22 0.01 
Nagelkerke R2 0.167 0.107 0.154 0.209 
Hosmer and Lemeshow test p Value 0.168 0.595 0.924 0.765 
 526 
Abbreviations: CI, confidence interval; EQ5D, European Quality of Life 5-Dimensions; HSS, Health State Score; MCS, Mental Component Score; OR, odds ratio; PCS, Physical Component 527 
Score; VAS, Visual Analogue Score. 528 




FIGURE LEGENDS 530 
Figure 1. The Consolidated Standards of Reporting Trials (CONSORT) flowchart of 531 
participant progression through the study. 532 




Supplementary Table 1. Multivariable linear regression analysis to identify independent determinants of health-related quality of life at baseline 534 




Mental component score Physical component score EQ5D Health state score EQ5D Visual analogue score 
B Beta p Value B Beta p Value B Beta p Value B Beta p Value 
Age (years) 0.323 0.361 <0.0001 0.054 0.055 0.5 0.004 0.215 0.008 0.200 0.120 0.2 
Sex (Male vs. Female) 0.118 0.005 1.0 0.352 0.013 0.9 -0.054 -0.091 0.3 -3.226 -0.068 0.5 
Unemployed/retired (Yes vs. No) -2.342 -0.085 0.3 -4.198 -0.140 0.07 -0.040 -0.062 0.4 -9.390 -0.182 0.04 
Dialysis modality (PD vs. HD) -0.374 -0.013 0.9 -4.546 -0.142 0.04 -0.109 -0.159 0.02 -5.499 -0.100 0.2 
SGA score 1.965 0.264 0.002 3.330 0.411 <0.0001 0.073 0.423 <0.0001 4.866 0.351 <0.0001 
Diabetes (Yes vs. No) -1.251 -0.051 0.5 -6.612 -0.247 0.001 -0.162 -0.284 <0.0001 -9.226 -0.202 0.02 
Dialysis vintage (months) 0.013 0.071 0.4 -0.017 -0.084 0.2 0.000 -0.061 0.4 0.019 0.056 0.5 
Handgrip strength (kg) -0.013 -0.013 0.9 0.140 0.122 0.2 0.004 0.151 0.1 -0.107 -0.054 0.6 
Adjusted R2 0.183 0.353 0.377 0.179 
 537 
Results presented as unstandardized (B) and standardized (Beta) coefficients.  538 
Abbreviations: EQ5D, European Quality of Life 5-Dimensions; HD, haemodialysis; PD, peritoneal dialysis; SGA, Subjective Global Assessment 539 
 540 
 541 




Supplementary Table 2. Predictors of change in health-related quality of life scores over one year in univariable analysis. 543 
 544 
Variable  Change in Mental Component Score Change in Physical Component Score Change in EQ5D Health State Score Change in EQ5D Visual Analogue Score 
 Increase/stable 
(n=74) 
Decrease (n=43) Increase/stable 
(n=75) 
Decrease (n=42) Increase/stable 
(n=59) 




Female (n=41)  


























Yes (n=51)  

























Coronary heart disease 
Yes (n=43)  


























Yes (n=29)  


























Yes (n=69)  




















































1-year change energy intake 
Increase/stable (n=66)  

























1-year change protein intake 
Increase/stable (n=54)  

























1-year change fat intake 
Increase/stable (n=64)  

























Age (years) 64 (IQR 55 to 75) 66 (53 to 74) 63 (54 to 73) 68 (55 to 76) 63 (53 to 73) 67 (55 to 76) 63 (53 to 75) 67 (55 to 74) 
1-year Δ Haemoglobin (g/L) -4.5 (-14.0 to 5.0) -4.0 (-12.0 to 6.0) -3.0 (-11.0 to 7.0) -9.0 (-18.0 to 0.3)* -3.0 (-14.0 to 5.0) -4.0 (-12.3 to 4.0) -5.0 (-14.0 to 6.0) -3.5 (-12.0 to 4.0) 
1-year Δ C reactive protein (mg/L) 0.3 (-5.0 to 3.0) 0.0 (-3.1 to 7.3) -0.1 (-4.8 to 2.5) 1.0 (-3.0 to 8.0) 0.0 (-3.0 to 4.0) 0.0 (-5.0 to 7.0) 0.0 (-6.0 to 8.0) 0.0 (-3.1 to 2.4) 
1-year Δ Serum creatinine (µmol /L) 4.5 (-64.5 to 117.5) 27.0 (-87.0 to 73.0) 23.0 (-36.0 to 96.0) -15.5 (-118.3 to 120.0) 25.0 (-62.0 to 132.0) 3.0 (-86.3 to 81.8) 25.0 (-76.5 to 122.5) 4.5 (-61.5 to 72.3) 
1-year Δ Serum albumin (g/L) 0.0 (-2.0 to 2.0) -1.0 (-4.0 to 1.0) 0.0 (-3.0 to 1.0) -1.0 (-3.3 to 1.0) 0.0 (-3.0 to 1.0) -1.0 (-3.0 to 1.0) 0.0 (-3.0 to 2.0) -1.0 (-3.0 to 0.8) 
1-year Δ Serum total protein (g/L) 0.5 (-3.0 to 4.0) -1.0 (-5.0 to 1.0) 1.0 (-4.0 to 3.0) -1.0 (-4.3 to 1.0)* 1.0 (-3.0 to 4.0) -1.0 (-4.0 to 3.0) 0.0 (-3.5 to 4.0) -0.5 (-4.0 to 2.0) 
1-year Δ Body mass index (kg/m2) -0.1 (-0.9 to 0.6) -0.5 (-1.3 to 0.3) -0.2 (-1.1 to 0.5) -0.1 (-1.2 to 0.7) -0.1 (-1.1 to 0.5) -0.2 (-1.1 to 0.7) -0.1 (-1.1 to 0.55) -0.4 (-1.2 to 0.7) 
1-year Δ Handgrip strength (kg) 0.2 (-1.9 to 2.9) -1.8 (-3.9 to 2.1) -0.5 (-2.3 to 2.9) 0.4 (-3.2 to 2.2) -0.1 (-3.1 to 3.2) -0.5 (-2.3 to 2.3) -0.6 (-2.9 to 3.1) 0.4 (-2.3 to 2.2) 
Abbreviations: EQ5D, European Quality of Life 5-Dimensions; IQR, interquartile range. 545 
Continuous variables expressed as median (interquartile range) and categorical variables expressed as numbers (percentage). 546 
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